Biogen (NASDAQ:BIIB) Lowered to Hold Rating by Jefferies Financial Group
Biogen (NASDAQ:BIIB – Get Free Report) was downgraded by equities research analysts at Jefferies Financial Group from a “buy” ...
Biogen reinstated with a Neutral at BofA
BofA reinstated coverage of Biogen (BIIB) with a Neutral rating and $178 price target Biogen is “a cheaper name,” mostly ...
Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown
Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains ...
Corcept Therapeutics' ALS drug fails in mid-stage trial
Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients ...
Biogen Inc. stock rises Wednesday, still underperforms market
The stock's rise snapped a four-day losing streak.
Biogen’s Modest Growth Prospects and Revenue Challenges Highlighted in Hold Rating
In a report released today, Michael Yee from Jefferies downgraded Biogen (BIIB – Research Report) to a Hold, with a price target of ...
Business Insider3d
Biogen downgraded to Hold from Buy at Jefferies
Pick the best stocks and maximize your portfolio: Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks ...
ETF Daily News5d
Public Sector Pension Investment Board Boosts Stake in Biogen Inc. (NASDAQ:BIIB)
BIIB has been the subject of a number of research reports ... a ranibizumab biosimilar referencing LUCENTIS. Receive News & ...
Biogen Inc. stock underperforms Monday when compared to competitors
Shares of Biogen Inc. BIIB slumped 0.84% to $156.46 Monday, on what proved to be an all-around dismal trading session for the ...
BofA restarts coverage of 11 large-cap biopharmas
BofA has reinstated coverage of 11 large-cap pharmaceutical and biotech stocks, with Eli Lilly (LLY), Gilead (GILD) and Merck ...
'Laggard' stocks with expanding FCF margins and attractive FCF yields – Goldman
Goldman Sachs listed their best free cash flow ideas, including Biogen (BIIB), Merck & Co. (MRK), and Regeneron Pharma (GEGN) ...
The Pharma Letter2d
Tim Power to head investor relations at Biogen
US biotech major Biogen today announced the appointment of Tim Power as vice president, head of investor relations, effective immediately. Mr. Power will report to Michael McDonnell, executive VP and ...